. 2020 Aug 11;9(1):129–144. doi: 10.1080/21556660.2020.1801452
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1.
Timeline of phase III studies of alirocumab and evolocumab.